Lung Transplant Rejection - Pipeline Review, H1 2018

  • ID: 4540565
  • Report
  • 58 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Kamada Ltd
  • MimeTech Srl
  • Novartis AG
  • Quark Pharmaceuticals Inc
  • TxCell SA
  • MORE
Lung Transplant Rejection - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights:

This latest pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 8 respectively.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Kamada Ltd
  • MimeTech Srl
  • Novartis AG
  • Quark Pharmaceuticals Inc
  • TxCell SA
  • MORE
Introduction

Report Coverage

Lung Transplant Rejection - Overview

Lung Transplant Rejection - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Lung Transplant Rejection - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lung Transplant Rejection - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Kamada Ltd

MimeTech Srl

Novartis AG

Quark Pharmaceuticals Inc

TxCell SA

Lung Transplant Rejection - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-1261 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FX-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPLI-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tacrolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tiprelestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zortress - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lung Transplant Rejection - Dormant Projects

Lung Transplant Rejection - Product Development Milestones

Featured News & Press Releases

Jan 08, 2018: Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Oct 09, 2017: Quark Pharmaceuticals to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference

Jun 19, 2017: TxCell Appoints Lentigen Technology To Manufacture the Lentiviral Vector for Its First CAR-Treg Program in Transplant Rejection

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs

Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Lung Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Lung Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2018

Lung Transplant Rejection - Pipeline by Kamada Ltd, H1 2018

Lung Transplant Rejection - Pipeline by MimeTech Srl, H1 2018

Lung Transplant Rejection - Pipeline by Novartis AG, H1 2018

Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1 2018

Lung Transplant Rejection - Pipeline by TxCell SA, H1 2018

Lung Transplant Rejection - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Lung Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astellas Pharma Inc
  • Kamada Ltd
  • MimeTech Srl
  • Novartis AG
  • Quark Pharmaceuticals Inc
  • TxCell SA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll